## SEC Form 4

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burder hours per response: 0.5

| 1. Name and Addres               | 1 0                 | 1*             | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>ANGIODYNAMICS INC [ ANGO ] |                        | tionship of Reporting Perso<br>all applicable)<br>Director                                    | 10% Owner                       |
|----------------------------------|---------------------|----------------|--|------------------------|---|---------------------------------|
| (Last)<br>603 QUEENSBU           | (First)<br>IRY AVE. | (Middle)       | 3. Date of Earliest Transaction (Month/Day/Year)<br>07/11/2005                   |                        | Officer (give title<br>below)<br>Vice President -   | Other (specify<br>below)<br>CFO |
| (Street)<br>QUEENSBURY<br>(City) | NY<br>(State)       | 12804<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)                         | 6. Indiv<br>Line)<br>X | idual or Joint/Group Filing (<br>Form filed by One Repor<br>Form filed by More than<br>Person | ting Person                     |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |                         |   | 4. Securities<br>Disposed Of |               |          | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|-------------------------|---|------------------------------|---------------|----------|---|---|---|
|                                 |  |   | Code                    | v | Amount                       | (A) or<br>(D) | Price    | Transaction(s)<br>(Instr. 3 and 4)  |   | (1130.4)  |
| Common Stock                    | 07/11/2005                                 |   | <b>M</b> <sup>(1)</sup> |   | 1,500                        | Α             | \$4.3478 | 1,631   | D   |   |
| Common Stock                    | 07/11/2005                                 |   | <b>S</b> <sup>(1)</sup> |   | 1,500                        | D             | \$24.28  | 131   | D   |   |

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)       | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of<br>Deri<br>Sec<br>Acq<br>(A) (<br>Disp<br>of (I | oosed<br>D)<br>tr. 3, 4 | 6. Date Exerci:<br>Expiration Dat<br>(Month/Day/Ye | e                  | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|--|-------------------------|--|--------------------|---|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A)  | (D)                     | Date<br>Exercisable                                | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy) | \$4.3478  | 07/11/2005                                 |   | M <sup>(1)</sup>             |   |  | 1,500                   | 12/30/2004   | 05/04/2008         | Common<br>Stock   | 1,500                                  | \$0   | 33,500   | D  |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy) | \$13.18   |  |   |                              |   |  |                         | 07/20/2005 <sup>(2)</sup>                          | 07/20/2014         | Common<br>Stock   | 10,200                                 |   | 10,200   | D  |  |
| Restricted<br>Stock<br>Units                              | \$0 <sup>(3)</sup>  |  |   |                              |   |  |                         | 05/30/2009   | 05/29/2019         | Common<br>Stock   | 4,000                                  |   | 4,000  | D  |  |

#### Explanation of Responses:

1. Transaction executed pursuant to an approved selling plan established under SEC rule 10b5-1.

2. Options for 25% of the shares are each exercisable on 7/20/05, 7/20/06, 7/20/07, 7/20/08, respectively.

3. Each restricted stock unit represents a contingent right to receive one share of AngioDynamics, Inc. common stock.

### By: Ronald F. Lamy For: Joseph G. Gerardi

07/12/2005

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Ronald F. Lamy, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of AngioDynamics, Inc., Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of April 2004.

/s/ Joseph G. Gerardi \_